Vistin Pharma Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Vistin Pharma.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 14.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vistin Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 427 | 61 | 56 | 100 | N/A |
| 6/30/2024 | 441 | 68 | 21 | 62 | N/A |
| 3/31/2024 | 441 | 56 | 35 | 74 | N/A |
| 12/31/2023 | 438 | 46 | 73 | 91 | N/A |
| 9/30/2023 | 439 | 45 | 39 | 77 | N/A |
| 6/30/2023 | 410 | 14 | 41 | 80 | N/A |
| 3/31/2023 | 373 | 7 | -29 | 17 | N/A |
| 12/31/2022 | 305 | -5 | -75 | -11 | N/A |
| 9/30/2022 | 272 | -15 | -90 | -51 | N/A |
| 6/30/2022 | 243 | -7 | -97 | -54 | N/A |
| 3/31/2022 | 241 | 1 | -51 | -5 | N/A |
| 12/31/2021 | 279 | 25 | -18 | 14 | N/A |
| 9/30/2021 | 265 | 26 | -19 | 42 | N/A |
| 6/30/2021 | 257 | 30 | -24 | 47 | N/A |
| 3/31/2021 | 263 | 43 | -186 | -129 | N/A |
| 12/31/2020 | 254 | -97 | -199 | -146 | N/A |
| 9/30/2020 | 246 | -102 | -174 | -133 | N/A |
| 6/30/2020 | 259 | -46 | -147 | -126 | N/A |
| 3/31/2020 | 247 | -67 | 19 | 34 | N/A |
| 12/31/2019 | 228 | 66 | 1 | 19 | N/A |
| 9/30/2019 | 212 | 4 | -14 | -8 | N/A |
| 6/30/2019 | 196 | -59 | -32 | -24 | N/A |
| 3/31/2019 | 190 | -72 | -60 | -40 | N/A |
| 12/31/2018 | 201 | -68 | -58 | -39 | N/A |
| 9/30/2018 | 200 | -16 | -33 | -5 | N/A |
| 6/30/2018 | 194 | -8 | N/A | -22 | N/A |
| 3/31/2018 | 186 | 8 | N/A | 13 | N/A |
| 12/31/2017 | 175 | 5 | N/A | 10 | N/A |
| 9/30/2017 | 168 | 10 | N/A | 6 | N/A |
| 6/30/2017 | 160 | 7 | N/A | 41 | N/A |
| 3/31/2017 | 170 | 14 | N/A | 25 | N/A |
| 12/31/2016 | 173 | 16 | N/A | 54 | N/A |
| 9/30/2016 | 393 | 40 | N/A | 100 | N/A |
| 6/30/2016 | 446 | 46 | N/A | 60 | N/A |
| 12/31/2015 | 376 | 33 | N/A | 53 | N/A |
| 12/31/2014 | 361 | -62 | N/A | 17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if VISTN's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if VISTN's earnings are forecast to grow faster than the Norwegian market
High Growth Earnings: Insufficient data to determine if VISTN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if VISTN's revenue is forecast to grow faster than the Norwegian market.
High Growth Revenue: Insufficient data to determine if VISTN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VISTN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 21:58 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |